{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.9","upperLimit":"8.3","value":"4.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Duration of response is the time from response (CR or PR) until progression of disease or relapse. Responses and progression were evaluated based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006).","dispersionType":"Full Range","groups":[{"description":"VELCADE given by intravenous push at 1.3 mg/m\\^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.\n\nCyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.\n\nChloroquine given at 500 mg orally daily on days 1-14 and 22-35.\n\nEach cycle is 42 days in length.","id":"OG000","title":"Velcade+Cyclophosphamide+Chloroquine"}],"paramType":"MEDIAN","populationDescription":"patients who have responded","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"Median Duration of Response of This Regimen","type":"SECONDARY","unitOfMeasure":"months"}